

Sélection des publications 2011

Azzopardi N, Lecomte T, Ternant D, Boisdrion-Celle M, Piller F, Morel A, Gouilleux-Gruart V, Vignault-Desvignes C, Watier H, Gamelin E, Paintaud G. Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. Clin Cancer Res 2011, 17 : 6329-6337

Beresniak A, Gossec L, Goupille P, Saraux A, Bamberger M, Bregman B, Dupont D. Direct cost-modeling of rheumatoid arthritis according to disease activity categories in France. J Rheumatol 2011, 38 : 439-445

Belmokhtar K, Bourguignon T, Worou ME, Khamis G, Bonnet P, Domenech J, Eder V. Regeneration of three layers vascular wall by using BMP2-treated MSC involving HIF-1 α and Id1 expressions through JAK/STAT pathways. Stem Cell Rev 2011, 7 : 847-859

Ben Nasr M, Reguaya Z, Berraies L, Maamar M, Ladeb S, Ben Othmen T, Mellouli F, Béjaoui M, Domenech J, Jenhani F. Association of stromal cell-derived factor-1-3'A polymorphism to higher mobilization of hematopoietic stem cells CD34+ in Tunisian population. Transplant Proc 2011, 43 : 635-638

Borowiec AS, Hague F, Gouilleux-Gruart V, Lassoued K, Ouadid-Ahidouch H. Regulation of IGF-1-dependent cyclin D1 and E expression by hEag1 channels in MCF-7 cells: The critical role of hEag1 channels in G1 phase progression. Biochim Biophys Acta 2011, 1813 : 723-730

Cayla G, Hulot JS, O'Connor SA, Pathak A, Scott SA, Gruel Y, Silvain J, Vignalou JB, Huerre, de la Briolle A, Allanic F, Beygui F, Barthélémy O, Montalescot G, Collet JP. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA 2011, 306 : 1765-1774

Daguet A, Watier H. 2nd Charles Richet et Jules Héricourt Workshop: Therapeutic antibodies and anaphylaxis; May 31-June 1, 2011, Tours, France (Meeting report). Mabs 2011, 3 : 417-421

Dhennin-Duthille I, Nyga R, Yahiaoui S, Gouilleux-Gruart V, Regnier A, Lassoued K, Gouilleux F. The tumor suppressor hTid1 inhibits STAT5b activity via functional interaction. J Biol Chem 2011, 286 : 5034-5042

Ducourau E, Mulleman D, Paintaud G, Chu Miow Lin D, Lauféron F, Ternant D, Watier H, Goupille P. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011, 13 : R105

Friedbichler K, Hoelbl A, Li G, Bunting KD, Sexl V, Gouilleux F, Moriggl R.
Serine phosphorylation of the Stat5a C-terminus is a driving force for transformation.
Front Biosci 2011, 16 : 3043-3056

Gaud G, lochmann S, Guillon-Munos A, Brillet B, Petiot S, Seigneuret F, Touzé A, Heuzé-Vourc'h N, Courty Y, Lerondel S, Gruel Y, Reverdiau P.
TFPI-2 silencing increases tumour progression and promotes metalloproteinase 1 and 3 induction through tumour-stromal cell interactions.
J Cell Mol Med 2011 15 : 196-208

Grandin N, Charbonneau M.
Rvb2/reptin physically associates with telomerase in budding yeast.
FEBS Lett 2011, 585 : 3890-3897

Gruel Y, Watier H.
Bacteria and HIT: a close connection? (editorial)
Blood 2011, 117 : 1105-1106

Jenhani F, Durand V, Ben Azouna N, Thallet S, Ben Othmen T, Bejaoui M, Domenech J.
Human cytokine expression profile in various conditioned media for in vitro expansion bone marrow and umbilical cord blood immunophenotyped mesenchymal stem cells.
Transplant Proc 2011, 43 : 639-643

Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G, Van Hoof A, Casasnovas O, Gyan E, Tilly H, Fruchart C, Deconinck E, Fitoussi O, Gastaud L, Delwail V, Gabarre J, Gressin R, Blanc M, Fousard C, Salles G; GELA and GOELAMS.
Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.
Haematologica 2011, 96 : 1128-1135

Maillet A, Guilleminault L, Lemarié E, Lerondel S, Azzopardi N, Montharu J, Congy-Jolivet N, Reverdiau P, Legrain B, Parent C, Douvin DH, Hureauux J, Courty Y, De Monte M, Diot P, Paintaud G, Le Pape A, Watier H, Heuzé-Vourc'h N.
The airways, a novel route for delivering monoclonal antibodies to treat lung tumors.
Pharm Res 2011, 28 : 2147-2156

Mamessier E, Sylvain A, Thibault ML, Houvenaeghel G, Jacquemier J, Castellano R, Gonçalves A, André P, Romagné F, Thibault G, Viens P, Birnbaum D, Bertucci F, Moretta A, Olive D.
Human breast cancer cells enhance self-tolerance by promoting evasion from NK cell antitumor immunity.
J Clin Invest 2011, 121 : 3609-3622

Méric JC, Mulleman D, Ducourau E, Lauféron F, Chu Miow Lin D, Watier H, Goupille P, Paintaud G.
Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label study.
Ther Drug Monit 2011, 33 : 411-416

Monjanel H, Deconinck E, Perrodeau E, Gastinne T, Delwail V, Moreau A, François S, Berthou C, Gyan E, Milpied N, on behalf of the GOELAMS.

Long-Term Follow-up of Tandem High-Dose Therapy with Autologous Stem Cell Support for Adults with High-Risk Age-Adjusted International Prognostic Index Aggressive non-Hodgkin's Lymphomas: a GOELAMS Pilot Study. Biol Blood Marrow Transplant 2011, 17 : 935-940 (IF2011 = 3,873)

Mulleman D, Lauferon F, Wendling D, Ternant D, Ducourau E, Paintaud G, Goupille P.

Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study.

Arthritis Res Ther 2011, 13 : R82

N'Guessan K, Ternant D, Labarthe F, Watier H.

Stability of IgE levels early in life.

J Allergy (Cairo) 2011, 2011 : 547389

Palazzoli F, Bire S, Bigot Y, Bonnin-Rouleux F.

Landscape of chromatin control element patents: positioning effects in pharmaceutical bioproduction.

Nat Biotechnol 2011, 29 : 593-597

Passeron T, Goupille P, Boulinguez S.

[Recommendations on the management of psoriatic arthritis].

Ann Dermatol Venereol 2011, 138 (6 Suppl 1): H10-2

Pham T, Bachelez H, Berthelot JM, Blacher J, Bouhnik Y, Claudepierre P, Constantin A, Fautrel B, Gaudin P, Goëb V, Gossec L, Goupille P, Guillaume-Czitrom S, Hachulla E, Huet I, Jullien D, Launay O, Lemann M, Maillefert JF, Marolleau JP, Martinez V, Masson C, Morel J, Mouthon L, Pol S, Puéchal X, Richette P, Saraux A, Schaeferbeke T, Soubrier M, Sudre A, Tran TA, Viguier M, Vittecoq O, Wendling D, Mariette X, Sibilia J.

TNF alpha antagonist therapy and safety monitoring.

Joint Bone Spine 2011, 78 Suppl 1 : 15-185

Warkentin TE, Greinacher A, Gruel Y, Aster RH, Chong BH; on behalf of the scientific and standardization committee of the international society on thrombosis and haemostasis.

Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis.

J Thromb Haemost 2011, 9 : 2498-2500

Wendling D, Prati C, Goupille P, Mulleman D.

Optimizing TNF α antagonist therapy in patients with spondyloarthritis : why and how?

Joint Bone Spine 2011, 78 : 225-227